Cargando…

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Systemic steroids are the standard first-line treatment for acute graft-versus-host disease (aGVHD), but ∼50% of patients become steroid-refractory or dependent (SR/D). Ruxolitinib is the only Food and Drug Administration– and European Medicines Agency–approved therapy for patients with SR/D aGVHD....

Descripción completa

Detalles Bibliográficos
Autores principales:	Socié, Gerard, Niederwieser, Dietger, von Bubnoff, Nikolas, Mohty, Mohamad, Szer, Jeff, Or, Reuven, Garrett, James, Prahallad, Anirudh, Wilke, Celine, Zeiser, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646803/ https://www.ncbi.nlm.nih.gov/pubmed/36827620 http://dx.doi.org/10.1182/blood.2022018579

Ejemplares similares

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease
por: Kim, Haesook T., et al.
Publicado: (2022)

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
por: Jentzsch, Madlen, et al.
Publicado: (2022)

Steroid Avoidance After Adult Living Donor Liver Transplant: A Cohort Analysis
por: Nunez, Miguel, et al.
Publicado: (2023)

Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study
por: Fein, Joshua A., et al.
Publicado: (2023)

A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft‐versus‐host disease
por: Pratta, Michael, et al.
Publicado: (2022)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission
por: Mitchell, Robert A., et al.
Publicado: (2018)

Prospective external validation of biomarkers to predict acute graft-versus-host disease severity
por: Robin, Marie, et al.
Publicado: (2022)

Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape
por: Greinix, Hildegard T., et al.
Publicado: (2022)

Effect of Early Steroid Withdrawal on Posttransplant Diabetes Among Kidney Transplant Recipients Differs by Recipient Age
por: Ahn, JiYoon B., et al.
Publicado: (2021)

One-Year Outcomes of a Cohort of Renal Transplant Patients Related to BMI in a Steroid-Sparing Regimen
por: Bellini, Maria Irene, et al.
Publicado: (2017)

Treatment of Chronic Active Antibody-mediated Rejection With Pulse Steroids, IVIG, With or Without Rituximab is Associated With Increased Risk of Pneumonia
por: Joachim, Emily, et al.
Publicado: (2020)

Intramesenteric Steroid Treatment for Steroid- Refractory Gastrointestinal Graft Versus Host Disease
por: Bilgin, Aynur Uğur, et al.
Publicado: (2012)

Early Steroid Withdrawal Compared With Standard Immunosuppression in Kidney Transplantation - Interim Analysis of the Amsterdam-Leiden-Groningen Randomized Controlled Trial
por: van Sandwijk, Marit S., et al.
Publicado: (2018)

Impact of Subclinical and Clinical Kidney Allograft Rejection Within 1 Year Posttransplantation Among Compatible Transplant With Steroid Withdrawal Protocol
por: Owoyemi, Itunu, et al.
Publicado: (2021)

UNOS/OPTN Data-guided Assessment of Focal Segmental Glomerulosclerosis After Kidney Transplantation and Evaluation of Immunosuppressive Protocols in a Steroid-free Center
por: Kurian, Sunil M., et al.
Publicado: (2021)

Steroid Response in Refractory Asthmatics
por: Jang, An-Soo
Publicado: (2012)

Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients
por: Bank, Jonna R., et al.
Publicado: (2016)

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
por: Kaloyannidis, Panayotis, et al.
Publicado: (2019)

T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy
por: Horgan, Claire, et al.
Publicado: (2023)

The impact of pulmonary function in patients undergoing autologous stem cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2021)

Low-dose Rituximab and Thymoglobulin Induction With Steroid-free Maintenance Immunosuppression and Protocol Biopsies Improves Long-term Patient and Graft Survival After Kidney Transplantation: Survival and Safety Outcomes in More Than 1100 Patients From a Single Center
por: Pathak, Vivek, et al.
Publicado: (2019)

Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis
por: Iizuka, Masahiro, et al.
Publicado: (2021)

Murine Models of Steroid Refractory Graft-versus-Host Disease
por: Toubai, Tomomi, et al.
Publicado: (2018)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
por: Weber, Daniela, et al.
Publicado: (2022)

A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease
por: Fløisand, Yngvar, et al.
Publicado: (2021)

Induction of Chimerism Permits Low-Dose Islet Grafts in the Liver or Pancreas to Reverse Refractory Autoimmune Diabetes
por: Zhang, Chunyan, et al.
Publicado: (2010)

Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease
por: Abedin, Sameem, et al.
Publicado: (2020)

T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity
por: Lum, Su Han, et al.
Publicado: (2022)

Patient and Graft Survival After A1/A2-incompatible Living Donor Kidney Transplantation
por: Bisen, Shivani S., et al.
Publicado: (2022)

Pharmacologic therapy for inflammatory bowel disease refractory to steroids
por: Martínez-Montiel, MP, et al.
Publicado: (2015)

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
por: Jung, Chul Won, et al.
Publicado: (2016)

Adult-Onset Acute Disseminated Encephalomyelitis Refractory to Steroids
por: AlZeera, Abdulla J, et al.
Publicado: (2021)

Cyclophosphamide for Refractory Acute Cellular Rejection After Lung Transplantation
por: Naik, Chetan, et al.
Publicado: (2018)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Treatment and unmet needs in steroid-refractory acute graft-versus-host disease
por: Malard, Florent, et al.
Publicado: (2020)

Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease
por: Kim, Hyun Min, et al.
Publicado: (2023)

Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease
por: Akahoshi, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_prms2pqs35n8atjbol5gtr9enn